Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
CTR20260773 Copper (64Cu) Oxodotreotide Neuroendocrine Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
CTR20260773 clinical trial report covering Copper (64Cu) Oxodotreotide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07464327 Risvutatug Rezetecan Non-squamous non-small cell lung cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07464327 clinical trial report covering Risvutatug Rezetecan, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07465263 SYH2053 Heterozygous familial hypercholesterolemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07465263 clinical trial report covering SYH2053, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07463573 MHB088C Metastatic Esophageal Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07463573 clinical trial report covering MHB088C, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07463651 Gilteritinib Fumarate Residual Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07463651 clinical trial report covering Gilteritinib Fumarate, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07463521 Rozanolixizumab Myasthenia Gravis, Ocular Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07463521 clinical trial report covering Rozanolixizumab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07465289 Rozanolixizumab Myasthenia Gravis, Ocular Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07465289 clinical trial report covering Rozanolixizumab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07467356 Bupivacaine Hydrochloride Pain Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07467356 clinical trial report covering Bupivacaine Hydrochloride, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07467330 Dalpiciclib Isethionate Metastatic breast cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07467330 clinical trial report covering Dalpiciclib Isethionate, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07467707 Chikungunya Vaccine, Recombinant (Bavarian Nordic) Chikungunya Fever Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07467707 clinical trial report covering Chikungunya Vaccine, Recombinant (Bavarian Nordic), Phase 3, endpoints, sponsor, geography, readout timing and d
Latest Hotspot
8 min read
CTR20260879 Ozenoxacin Suppuration Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
CTR20260879 clinical trial report covering Ozenoxacin, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07468448 Rivaroxaban Atherosclerosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07468448 clinical trial report covering Rivaroxaban, Phase 3, endpoints, sponsor, geography, readout timing and development white space.